LA
VRTX icon

Leonetti & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Leonetti & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,475
Closed -$6.6M – 42
2018
Q1 		$6.6M Buy
+40,475
New +$6.61M 1.91% 14

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Leonetti & Associates's VRTX Position: Q2 2018 in Review

Leonetti & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 40,475 shares — an estimated $6.6M sold.

Leonetti & Associates first reported a position in VRTX in Q1 2018 and held it in 1 quarter. The position peaked at $6.6M in Q1 2018. 689 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

  • Leonetti & Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Leonetti & Associates sold 40,475 Vertex Pharmaceuticals shares in Q2 2018, an estimated $6.6M.
  • Leonetti & Associates first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Leonetti & Associates's Vertex Pharmaceuticals position peaked at $6.6M in Q1 2018.
  • 689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Leonetti & Associates's 13F filing for Q2 2018, filed 15 Aug 2018.